企业强则国家强，企业兴则国家兴。国有企业是中国特色社会主义经济的"顶梁柱"，随着我国经济结构 不断调整优化，如何推动国资国企高质量发展，充分发挥国民经济"领头羊"作用？广西壮族自治区出台 了一系列政策措施，做好"原字号""老字号""新字号""外字号"四篇强产业文章，着力培育经济增长新动 力、做优做强传统产业、加快提升国际化经营水平，国资国企不断"破圈"成长。 今年是国有企业改革深化提升行动的收官之年，改革如何走深走实？科技创新持续加力，产业发展向新 求质，国企改革扎实推进……诸多新成效传递着地方国资国企加快高质量发展的积极信号。 为充分发挥国有企业引领高质量发展的主力军作用，近年来，广西壮族自治区国资委出台政策措施鼓励 国有企业培育壮大"新字号"、转型升级"老字号"、科技赋能"原字号"、加快发展"外字号"，产业发展焕 发勃勃生机。数据显示，2025年上半年，广西国资委监管企业利润总额、战略性新兴产业投资、主业投 资占比同比分别增长13.56%、20.66%、2.55%。 培育壮大"新字号" 在今年的上海车展上，柳州五菱汽车工业有限公司成为众人瞩目的焦点。这是五菱工业公司第三次亮相 全球顶级车展。他们自主研发的 ...

Group 1 - Zhongheng Group successfully acquired a Class 1 innovative drug project for treating chronic heart failure, marking a significant addition to its cardiovascular treatment pipeline [1] - The newly introduced drug targets myocardial energy metabolism regulation, addressing unmet clinical needs in chronic heart failure treatment [1] - The acquisition aligns with Zhongheng Group's strategic focus on core disease areas and enhances synergy with existing products [1] Group 2 - Zhongheng Group has increased its R&D investment, totaling 604 million yuan from 2021 to 2024, which accounts for 5.37% of its operating income [2] - The company has initiated over 80 scientific innovation projects in the past five years, including six Class 1 innovative drug projects [2] - Notable achievements include the approval of "Sanqi Granules" for clinical trials and the successful launch of a unique injection for glioma treatment [2]

Group 1 - The project "Research and Development Application Demonstration of the Theory of 'Nature-Effect-Material' of Traditional Chinese Medicine and Ethnic Medicine" led by Guangxi Wuzhou Pharmaceutical Co., Ltd. won the second prize of the Guangxi Science and Technology Progress Award for 2024 [1] - The project aims to reveal the efficacy material basis of traditional Chinese medicine and enhance the modernization level of traditional drugs, showcasing Wuzhou Pharmaceutical's strength in the field of modernization of traditional Chinese medicine [1] - The product "Chinese Die Da Wan," exclusively produced by Wuzhou Pharmaceutical, has been clinically applied for over 50 years and is recognized for its significant effects in orthopedic treatment [1] Group 2 - The "Secondary Development Research of Chinese Die Da Wan" project, completed in collaboration with Guangxi University of Traditional Chinese Medicine, significantly improved the quality control standards of the product and clarified its clinical application direction [2] - Wuzhou Pharmaceutical and other subsidiaries of Zhongheng Group won 8 awards at the 13th National Brand Story Competition (Beihai Division), including 2 excellent awards, 4 strength awards, and 2 potential awards [2] - The recognition at the National Brand Story Competition reflects the strong brand building efforts and innovative development philosophy of Zhongheng Group [2]

Core Insights - The "Digital Commerce Promotes Agriculture" initiative is being implemented in Wuzhou, Guangxi, highlighting the city's industrial heritage and its role as a hub for various well-known brands [1][3] - Wuzhou's artificial gemstone industry is a significant contributor to the global market, with an annual production accounting for 80% of China's and 70% of the world's output [1] Group 1: E-commerce Development - Wuzhou has seen a deep integration of traditional industries with e-commerce, utilizing platforms like Douyin and Taobao to showcase local products such as Liu Bao tea and artificial gemstones [3] - The city has achieved over 100 million yuan in online sales of agricultural products this year, indicating a strong growth in e-commerce [4] Group 2: Cross-border E-commerce Initiatives - Wuzhou has been approved as a comprehensive pilot zone for cross-border e-commerce, establishing key facilities like bonded warehouses and a live-streaming base to enhance its e-commerce ecosystem [4] - The city has recognized 13 enterprises as "vegetable basket" production bases in the Guangdong-Hong Kong-Macao Greater Bay Area, enhancing its agricultural supply chain [4] Group 3: Agricultural Processing and Value Addition - In 2024, Wuzhou's agricultural processing output value is expected to exceed 20.9 billion yuan, with a processing conversion rate of 73.28%, showcasing the effectiveness of its agricultural development strategy [4] - The establishment of seven agricultural processing clusters has significantly contributed to the development of the agricultural industry chain in Wuzhou [4]

Core Viewpoint - 中恒集团 is focusing on enhancing its market strategies and expanding its product offerings in both the pharmaceutical and health sectors, while also exploring potential mergers and acquisitions to strengthen its position in the industry [1][2][5]. Group 1: Business Strategies - The company is implementing personalized market strategies through regional collaboration, focusing on key products like 血栓通 and 中华跌打丸 to expand its marketing and sales efforts [2]. - It aims to deepen its market penetration by developing specialized marketing teams and establishing sales channels that radiate from provincial capitals to surrounding areas [2]. - The company is leveraging new media and exhibitions to enhance brand visibility and expand its sales network [2]. Group 2: Product Development - 中恒集团 has launched 154 new health products in 2024, with 51 already in production, while continuing to promote its traditional product, 双钱龟苓膏 [3]. - The company is focusing on core health food products and expanding its sales channels to achieve growth in both pharmaceutical and health food sectors [4]. Group 3: Growth Opportunities - The company identifies several growth points, including expanding its blood thrombus product market, enhancing the coverage of its跌打丸 product, and increasing e-commerce sales [4]. - It is also innovating in the daily chemical sector and exploring international markets, particularly in Southeast Asia, through partnerships [4]. Group 4: Financial Performance - In Q1 2025, 中恒集团 reported a revenue of 742 million yuan, a year-on-year decrease of 7.92%, and a net profit of 18.27 million yuan, down 66.61% [7]. - The company's debt ratio stands at 31.89%, with a gross profit margin of 29.62% [7]. Group 5: Share Buyback - The company plans to conduct a share buyback within a range of 300 million to 500 million yuan, with the first buyback executed on April 10, 2025, totaling approximately 42.15 million shares [6].